Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity
Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity
复制标题
DOI：
10.1111/j.1349-7006.2008.00949.x
复制
发表时间：
2008-10-01
期刊：
影响因子：
5.7
通讯作者：
Takahashi, Masahide
中科院分区：
文献类型：
--
作者：
Hagiwara, Sumitaka;Murakumo, Yoshiki;Takahashi, Masahide
CD 109是一种糖基磷脂酰肌醇（GPI）锚定的糖蛋白，其表达在肺、食管和子宫的鳞状细胞癌（SCC）中上调。本研究的目的是评估CD 109在口腔肿瘤（包括癌前病变）中的表达，并评估CD 109在口腔癌中的临床应用。应用免疫组化方法检测124例口腔癌组织和正常口腔黏膜组织中CD 109的表达，并分析其与临床特征的关系。我们发现，高水平的CD 109表达经常检测到SCC和癌前病变的口腔，而不是在正常鳞状上皮。CD 109在高分化SCC中的表达水平高于低分化SCC。此外，高表达CD 109的癌前病变进展为SCC的风险更高。与对照细胞系相比，过表达CD 109的口腔鳞状细胞癌细胞系在体外表现出加速的细胞生长。此外，CD 109的过表达损害了转化生长因子（TGF）-β 1介导的细胞生长抑制。这些发现表明，CD 109在口腔癌的发展中起作用，是一个有用的预后指标，以预测恶变的癌前病变。（Cancer Sci 2008; 99：1916-1923）
CD109 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein whose expression is up-regulated in squamous cell carcinomas (SCCs) of the lung, esophagus, and uterus. The purpose of this study was to evaluate CD109 expression in oral tumors, including premalignant lesions, and to assess the clinical application of CD109 in oral cancer. CD109 expression in oral normal and tumor tissues from 124 patients was examined by immunohistochemical staining with anti-CD109 antibody, and significant relations between clinical features and CD109 expression were statistically assessed. We found that high levels of CD109 expression were frequently detected in SCCs and premalignant lesions of the oral cavity, but not in normal squamous epithelia. The CD109 expression level was higher in well-differentiated SCCs than in poorly differentiated SCCs. Furthermore, premalignant lesions highly expressing CD109 showed higher risk to progress to SCCs. Oral SCC cell lines overexpressing CD109 exhibited accelerated cell growth in vitro compared with control cell lines. In addition, overexpression of CD109 impaired the transforming growth factor (TGF)-beta 1-mediated suppression of cell growth. These findings suggest that CD109 plays a role in the development of oral cancers, and is a useful prognostic marker to predict malignant transformation of premalignant lesions. (Cancer Sci 2008; 99: 1916-1923)